AbbVie Inc (ABBV)

ABBV (NYSE:Drugs)
$67.71
pos +0.00
+0.00%
Today's Range: 66.84 - 68.62 | ABBV Avg Daily Volume: 12,323,200
Last Update: 12/19/14 - 4:06 PM EST
Volume: 0
YTD Performance: 28.21%
Open: $0.00
Previous Close: $67.92
52 Week Range: $45.50 - $70.76
Oustanding Shares: 1,593,265,381
Market Cap: 108,214,584,678
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 7 6 5 5
Moderate Buy 0 1 0 0
Hold 3 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.60 1.65 1.57 1.57
Latest Dividend: 0.49
Latest Dividend Yield: 2.89%
Dividend Ex-Date: 01/13/15
Price Earnings Ratio: 29.53
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
29.53 29.40 25.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
14.65% 28.65% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.20 0.00 0.00
Net Income -21.70 0.00 0.00
EPS -23.10 0.00 0.00
Earnings for ABBV:
EBITDA 6.56B
Revenue 18.79B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $0.85 $0.82 $3.30 $4.30
Number of Analysts 5 1 8 9
High Estimate $0.90 $0.82 $3.38 $4.68
Low Estimate $0.82 $0.82 $3.25 $3.70
Prior Year $0.82 $0.72 $3.14 $3.30
Growth Rate (Year over Year) 3.66% 13.89% 4.94% 30.37%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

Three Large-Cap Growth Stocks Real Money Pro($)

I would pick up some large caps on any significant dips.
Bearish
Dec 11, 2014 | 7:20 AM EST
ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. $72 price target. Stock is already pricing in potential for H...

Buy Gilead Sciences Real Money Pro($)

Its prospects exploded with a breakthrough drug.
Bearish
Nov 07, 2014 | 7:51 AM EST
ABBV downgraded to Market Perform from Outperform, said BMO. Stock price reflects high expectations on Hep-C opportunity.
Bullish
Oct 22, 2014 | 7:21 AM EDT
ABBV estimates were raised through 2015, BMO Capital said. Expect the company to exceed consensus and Hep-C can drive future growth. Ou...
There is virtually no room for error in a crowded trade.
We now have an investable bottom on our hands.
It's unlikely that they will be hit by Europe or the Ebola scare. 
There will likely be more selling until the elusive bottom is reached.

This Morning's Market Setup Real Money Pro($)

 Where it began.

Columnist Conversations

The prominence (and amount of) of the discounting in the malls this weekend has been very noticeable. One are...
3 insiders sold a total of 518,620 Starbucks (SBUX) shares for proceeds of $43.449 MM. 4 insiders dumped 558,1...
Yum Brands saw both insider buying and selling reported last week. One insider bought 10,000 shares for about ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.